InspireMD

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InspireMD reports strong Q1 performance, eyes future growth opportunities

InspireMD's Q1 2024 showcased revenue growth and promising trial results, but challenges in gross profit and rising expenses. Strategic agreements and upcoming product approvals present opportunities for future growth and innovation.

InspireMD reports revenue growth, faces cost challenges, eyes U.S. launch

InspireMD's Q2 2024 performance reflects revenue growth but challenges in managing costs and achieving profitability.
The company's strengths lie in groundbreaking clinical outcomes, successful financings, and preparations for a U.S. commercial launch.
While facing cost and financial challenges, InspireMD has opportunities to drive market expansion, innovation, and capitalize on its strong cash position.
Balancing growth initiatives with cost control will be key for InspireMD's sustainable financial success and market competitiveness.

InspireMD reports 16% revenue growth in Q3 2024 earnings call

InspireMD's Q3 performance reflects revenue growth but challenges in profitability due to cost dynamics.
The company's strategic strengths lie in international sales, product innovation, and U.S. market focus.
Opportunities include FDA approvals, market expansion, and strong financial position for growth initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023.

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

InspireMD, Inc. (NASDAQ:NSPR ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Chuck Padala - IR, Life Advisors Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Conference Call Participants Adam Maeder - Piper Sandler Operator Good day, everyone, and welcome to the InspireMD Third Quarter 2024 Earnings Call. Currently, all participants are in a listen-only mod e.

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.15 per share a year ago.

InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates

MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of its global headquarters in Miami, Florida. The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved.

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

NSPR gains premarket approval for its CGuard Prime carotid stent system for use in United States for treating carotid artery stenosis.

InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent

MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures.

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.

NSPR Stock Declines Despite PMA Application Submission for CGuard

PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

InspireMD, Inc. (NASDAQ:NSPR ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Chuck Padala - IR, Life Advisors Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Conference Call Participants Adam Maeder - Piper Sandler Frank Takkinen - Lake Street Capital Markets Operator Good morning, and welcome to the InspireMD Second Quarter 2024 Earnings Call. Currently, all participants' are in a listen-only mode.

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.

InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates

- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial –

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials CREST-2 included 23 cases implanted with CGuard TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today congratulated the lead investigators on the completion of enrollment in the CREST-2 (Carotid Revascularization Endarterectomy or Stenting Trial) clinical trials. The CGuard carotid stent, utilizing its proprietary MicroNet™ mesh, was included as a device option for stenting in the CREST-2 trials following FDA approval of InspireMD's Investigational Device Exemption (IDE) supplement application in February 2022.

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2024 financial results on Tuesday, August 6th, before the financial markets open.

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

InspireMD Inc. (NASDAQ:NSPR ) Q1 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Chuck Padala - Managing Director Marvin Slosman - President, CEO & Director Craig Shore - CFO, Chief Administrative Officer, Secretary & Treasurer Conference Call Participants Adam Maeder - Piper Sandler Operator Greetings, and welcome to the InspireMD First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

- Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 -

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open.   Management will host a conference call and webcast with the investment community at 8:30 am (EDT) that same day to review financial results and provide an update on corporate developments.

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024.

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig, Germany.

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

InspireMD Inc. (NASDAQ:NSPR ) Q4 2023 Earnings Conference Call March 6, 2024 8:30 AM ET Company Participants Charles Padala - Investor Relations, LifeSci Advisors Marvin Slosman - President and Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Ben Haynor - Alliance Global Partners Operator Greetings. Welcome to InspireMD Fourth Quarter and Full Year 2023 Earnings Call.

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company's ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Prime - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D.

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial results on Wednesday, March 6th, 2024, before the financial markets open.

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Development of SwitchGuard™ consistent with Company's mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform Development of SwitchGuard™ consistent with Company's mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.

News for InspireMD Stock (NSPR)